data expect quarter tweak
forma cash octob equiti rais
principia complet ipo sept
quarterli ep may add due increas share count
round posit ep base dilut share count
expans topic btk inhibitor applic suspens
earli focu effort immun disord
morn principia announc expans btk inhibitor
franchis immune-medi diseas initi new
program topic suspens oncolog asset
bladder cancer strateg move busi
clinic refocus btk inihibitor franchis immune-medi
indic topic revers coval btk inhibitor
design administ topic like address
immune-rel disord requir local target approach
rather system rout administr phase trial
topic slate begin australia expect
complet trial random double-blind placebo-
control singl multipl dose studi aim evalu
drug safeti toler pk/pd new addit principia
advanc three proprietari differ separ rout btk
inhibit system topic view may suggest
patient multipl diseas indic could potenti
address beyond current one pv itp diseas
rd also three program conceiv principia
import releas phase data expect
sanofi sni rate advanc prnb brain tropic
btk inhibitor releas phase data
expect note principia option co-fund
phase trial follow phase data importantli sanofi capit
market day decemb compani highlight uniqu
competit advantag oppos
merck rate non-brain tropic btk inhibitor evobrutinib
specif brain-penetr molecul
get diseas microglia cell brain wherea evobrutinib
also anoth key differ higher safeti profil
comment select btk inhibitor
seen off-target issu liver transaminas elev
seen competitor molecul moreov sanofi manag
comment show posit data
compani may start four phase studi relapsing-remit primari
progress secondari progress readi launch
get data need overal confid
program deriv promis pk/pd data hand
dose escal phase studi highlight abil reach
brain tissu impact cell-driven inflamm local highli
differenti main peer merck evobrutinib valid
btk target ms evobrutinib pharma partnership
valid lastli cross blood-brain barrier bbb potenti
crucial hit patholog inflammatori pathway microglia cell
act brain macrophag lead better target engag
definit distribut analyst rate analyst certif disclosur pleas refer page report
posit progress kol feedback citp result meet principia present posit
clinic data itp host kol event data updat kol comment crucial takeaway
presenc medic need market potenti could signific novel drug candid
new clinic relev moa citp rapid onset activ favor safeti profil suggest
potent safer btk inhibitor complet analysi trial patient target go present
upcom medic confer detail data releas discuss could found
recent note referenc itp data shine
expans diseas rd initi phase trial earlier week compani also
announc new initi potenti clinic commerci expans highlight
indic target therapi thu far analyz patholog onset indic note immune-
mediat disord character chronic inflamm fibrosi target cell autoantibodi product
could clinic relev might address mani aspect potenti affect
patholog featur diseas inflamm allerg compon ige eosinophil monocyt
macrophag involv fibrosi cell prolifer given high rate relaps current therapeut option includ
rituxan glucocorticoid satisfactori principia believ proven effect safe monotherapi
could becom attract drug candid compani anticip initi phase clinic trial interestingli
american colleg rheumatolog european leagu rheumat recent publish new diagnosi
treatment guidelin might facilit futur clinic develop new target approach
new guidelin led dr john stone md mph director clinic rheumatolog massachusett gener hospit
associ professor medicin divis rheumatolog harvard medic school
anticip data time pivot phase pegasu trial pv vs prior guid principia continu
progress lead drug candid rilzabrutinib new gener name pivot pegasu studi pemphigu
vulgari pv recent compani announc trial may experi faster-than-anticip releas final result
oppos mainli due increas acceler enrol note on-going part phase
trial pv demonstr posit clinic result cr encourag major patient
receiv sub-optim therapeut dose drug mg daili discuss may expect final result
phase part trial upcom medic confer detail analysi part phase
studi pv could found recent note referenc consist messag day pv efficaci
sanofi anticip phase trial data multipl sclerosi
present pemphigu phase part trial
initi phase trial
present itp phase trial
pegasu phase trial result acceler
initi phase trial
valuat risk price target achiev reiter buy rate reduc price target
base remov project current valuat base opportun pv
follow increment contribut itp ms pv project launch
 base project chanc success billion million peak sale respect
itp model opportun project launch chanc success million peak
sale ms project launch chanc success billion peak sale
believ conserv current valu immunoproteasom program price target base clinic
net present valu npv model allow us flex multipl assumpt affect drug potenti commerci profil
factor could imped reach price target includ fail inconclus clinic trial inabl compani
secur adequ fund progress drug develop pathway
million except per share data
licens revenu
product royalti
provis tax
particip prefer stock
net incom common
number share basic
number share dilut
sec file wainwright estim
principia complet ipo septemb
licens revenu
product royalti
provis tax
particip prefer stock
net incom common
sec file wainwright estim
principia complet ipo septemb
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori principia biopharma inc prnb-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl januari
 wainwright co llc firm member finra sipc regist broker-deal
joseph pantgini ph certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli
relat specif recommend view express research report neither member
household offic director advisori board member compani
none research analyst research analyst household financi interest secur principia
biopharma inc includ without limit option right warrant futur long short posit
decemb neither firm affili benefici class common equiti secur
inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within twelv
month seek compens compani mention report invest bank servic within
three month follow public research report
 wainwright co llc manag co-manag public offer secur inc
firm make market inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
